RG7795

RG7795
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Investigational
CAS Number	1174920-78-5
PubChem
DrugBank
ChemSpider
KEGG

RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.<ref name=Adis>

RG 7795(link). {{{website}}}. AdisInsight.

</ref> It is an orally-available prodrug of isatoribine,<ref name=Funk>,

 Tickling the TLR7 to cure viral hepatitis., 
 Journal of Translational Medicine, 
 
 Vol. 12,
 pp. 129,
 DOI: 10.1186/1479-5876-12-129,
 PMID: 24884741,
 PMC: 4039542,</ref> that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.<ref>

,

 Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration Full text, 
 Genetic Engineering News, 
  
 August 3, 2016,

</ref> Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.<ref name=Funk/>

References

<references/>

   This article is a medical stub. You can help WikiMD by expanding it!

RG7795

• 
  RG-7795
• 
  Isatoribine